CEO and Founder of Foresite Capital
Jim Tananbaum is CEO and founder of Foresite Capital with $1.1 billion in assets under management. Jim has more than 20 years experience investing and building healthcare companies. Prior to founding Foresite Capital, Jim co-founded two leading biopharmaceutical companies and two healthcare investment practices. While finishing Harvard Medical School, he founded GelTex Pharmaceuticals (NASDAQ:GENZ), which brought two drugs to market for less than $80 million; today these drugs generate $1 billion in revenues. GelTex was acquired for $1.6 billion. Jim also founded and was CEO of Theravance, Inc. (NASDAQ: THRX), which together with its spin-off Theravance Biopharma, Inc. (NASDAQ: TBPH) has a combined market cap of $2.75 billion. On the investment side, Jim was a founding partner of Prospect Venture Partners II and III, and earlier in his career, Jim was a partner at Sierra Ventures where he helped establish their healthcare services investment practice. Jim has led numerous investments including Amira Pharmaceuticals (acquired by NYSE: BMS), Amerigroup (NASDAQ: AMGP), Healtheon (NASDAQ:WBMD), and Jazz Pharmaceuticals (NASDAQ: JAZZ). Jim graduated from Yale with a B.S. and B.S.E.E., graduated with an M.D. from Harvard Medical School, M.S. From MIT and an M.B.A from Harvard Business School. He has served on the advisory boards and/or visiting committees to the Harvard-MIT HST program and Yale’s President Advisory Counsel.